CAS 1977495-97-8

Trilaciclib hydrochloride

CAS : 1977495-97-8

Trilaciclib hydrochloride (G1T28 hydrochloride) is an inhibitor of CDK4/6 (IC50s: 1 nM and 4 nM for CDK4 and CDK6).

Formule : C₂₄H₃₂Cl₂N₈O

Degré de pureté : 99.69% - 99.89%

Couleur et forme : Solid

Masse moléculaire : 519.47

Ref: TM-T13202

7',8'-Dihydro-2'-[[5-(4-methyl-1-piperazinyl)-2-pyridinyl]amino]spiro[cyclohexane-1,9'(6'H)-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one dihydrochloride

CAS : 1977495-97-8

Formule : C₂₄H₃₂Cl₂N₈O

Degré de pureté : 99%

Couleur et forme : Solid

Masse moléculaire : 519.4699

Ref: IN-DA01EOQ0

Trilaciclib hydrochloride

CAS : 1977495-97-8

Trilaciclib hydrochloride

Degré de pureté : ≥98%

Masse moléculaire : 519.47g/mol

Ref: 54-BUP08915

Trilaciclib hydrochloride

CAS : 1977495-97-8

Trilaciclib is a small molecule that inhibits the CDK4/6 complex and is an inhibitor of cell proliferation. It has been shown to inhibit cancer growth in vitro, in vivo, and in humans. Trilaciclib is currently being tested as a treatment for hormone-dependent breast cancer. The drug works by targeting the microenvironment and inhibiting fibroblast growth factor (FGF) from binding to its receptor on the surface of cells. This leads to cell death through apoptosis and immunogenic cell death, which can be used for the treatment of tumors. Trilaciclib also enhances natural killer cell activity, which may help with cancer patients’ immunity against tumor cells.

Formule : C₂₄H₃₂Cl₂N₈O

Degré de pureté : Min. 95%

Couleur et forme : Powder

Masse moléculaire : 519.47 g/mol

Ref: 3D-CED49597